CellSeed Inc. (7776) AI Stock Analysis

0 Followers

CellSeed Inc.

(TSE/TYO:7776)

Select Model

Rating:44Neutral

Price Target:JPY 164.00▼(-2.96% Downside)

Action:reiterated

Date:09/06/26

The score is primarily held back by weak financial performance—sharp revenue decline, very large losses, and persistent cash burn—despite relatively low leverage. Technicals also point to a downtrend (below key moving averages and negative MACD). Valuation is difficult to support with a negative P/E and no dividend yield provided.

Positive Factors

Conservative leverageLow leverage gives CellSeed more financial flexibility than a heavily indebted biotechnology company and limits fixed financing obligations. This can help preserve strategic options while therapies and supporting technologies remain under development, although continued losses still require careful funding management.

Negative Factors

Sharp revenue contractionThe sharp 2025 revenue decline weakens evidence of commercial traction and makes near-term scaling more difficult. Sustained revenue volatility can reduce operating leverage, complicate planning, and leave the company more dependent on external funding while its regenerative medicine programs develop.

CellSeed Inc. (7776) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 6.70B
Dividend Yield: ―
Average Volume (3M): 179.38K
Price to Earnings (P/E): -5.8
Beta (1Y): 1.19
Revenue Growth: -49.43%
EPS Growth: -3.77%
Country: Japan
Employees: 36
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CellSeed Inc. Business Overview & Revenue Model

Company Description

CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass ep...

CellSeed Inc. Financial Statement Overview

Summary

Income statement and cash flow are weak (Income Statement Score 18; Cash Flow Score 16) due to sharply lower 2025 revenue and very large, widening losses with sustained cash burn. The balance sheet is comparatively healthier (Balance Sheet Score 57) with low leverage, but declining equity and deeply negative returns underscore ongoing funding and dilution risk.

Income Statement

18Very Negative

Balance Sheet

57Neutral

Cash Flow

16Very Negative

Financial statement breakdown
Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	83.68M	193.28M	190.13M	126.43M	161.67M
Gross Profit	42.75M	110.11M	107.16M	61.02M	84.04M
EBITDA	-1.05B	-855.49M	-836.52M	-750.00M	-905.67M
Net Income	-1.10B	-859.84M	-846.53M	-759.68M	-912.87M
Balance Sheet
Total Assets	1.66B	2.43B	2.47B	1.54B	1.41B
Cash, Cash Equivalents and Short-Term Investments	1.32B	2.13B	2.16B	1.07B	846.67M
Total Debt	132.92M	143.75M	151.25M	158.75M	160.00M
Total Liabilities	387.46M	269.88M	301.05M	365.58M	363.58M
Stockholders Equity	1.27B	2.16B	2.16B	1.18B	1.04B
Cash Flow
Free Cash Flow	-1.02B	-884.47M	-801.07M	-733.60M	-908.15M
Operating Cash Flow	-988.98M	-866.10M	-779.43M	-718.01M	-817.15M
Investing Cash Flow	-26.72M	-18.37M	56.31M	61.73M	-110.44M
Financing Cash Flow	200.30M	855.48M	1.81B	881.81M	396.88M

CellSeed Inc. Technical Analysis

Technical Analysis SentimentNegative

Last Price169.00

Price Trends

50DMA205.40Negative

100DMA213.85Negative

200DMA251.88Negative

Market Momentum

MACD-11.25Positive

RSI33.71Neutral

STOCH38.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Negative. The current price of 169.00 is below the 20-day moving average (MA) of 184.15, below the 50-day MA of 205.40, and below the 200-day MA of 251.88, indicating a bearish trend. The MACD of -11.25 indicates Positive momentum. The RSI at 33.71 is Neutral, neither overbought nor oversold. The STOCH value of 38.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7776.

CellSeed Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:7776 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:7096	58Neutral	JPY 6.67B	58.54	―	―	2.55%	-43.06%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4978	45Neutral	JPY 11.65B	-25.06	―	―	-8.23%	-48.10%
JP:7776	44Neutral	JPY 6.70B	-5.83	―	―	-49.43%	-3.77%
JP:7774	42Neutral	JPY 26.52B	-73.78	―	―	17.05%	10.47%
JP:4593	39Underperform	JPY 30.90B	-13.76	―	―	-51.55%	52.19%
JP:4599	38Underperform	JPY 7.33B	-3.94	―	―	―	4.85%

* Healthcare Sector Average

Performance Comparison

JP:7776 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:7776	CellSeed Inc.	169.00	-232.00	-57.86%
JP:4593	Healios KK	228.00	-223.00	-49.45%
JP:4599	StemRIM Inc.	117.00	-161.00	-57.91%
JP:4978	ReproCELL Inc.	109.00	-48.00	-30.57%
JP:7096	StemCell Institute	651.00	-144.00	-18.11%
JP:7774	Japan Tissue Engineering Co., Ltd.	653.00	175.00	36.61%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

CellSeed Inc. AI Stock Analysis